Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Adams Harkness Cuts Pharmacyclics to Market Perform


Adams Harkness downgrades Pharmacyclics (PCYC) to market perform from buy after the company says that two primary endpoints for Xcytrin injection, its lead drug in testing, were not met.

Analyst Felicia Reed says the company reported negative Phase III trial data for Xcytrin, a radiation sensitizer, in patients with brain metastases. She says that the median survival in patients who received Xcytrin plus radiation was 5.2 mos, not statistically very different from 4.9 months survival of patients who only received radiation. With viability of the drug in question, there's little in the company's pipeline to fuel near-term enthusiasm. Reed thinks shares will hover around the $8 level that she expects will be reached today.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus